Conversations with Oncology Investigators Bridging the Gap between Research and Patient Care

Submitted by nenadkesic@gmail.com on Mon, 11/27/2017 - 06:59

Listen to streaming audioright from your computer
Download programto your desktop
Sign up for podcastto have this and future issues delivered to your iTunes library

Audio Highlights

Interview with Daniel J DeAngelo, MD, PhD

Track 1:	Case: A 21-year-old woman presents with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (ALL) and is found to have an E2A-Pbx1 translocation
Track 2:	Biologic rationale for the use of pediatric regimens for young adult patients with ALL
Track 3:	Importance of Philadelphia chromosome status and Philadelphia-like signature in prognosis and treatment approach
Track 4:	Cooperative care of patients with ALL between community practices and tertiary centers
Track 5:	Treatment selection strategy for patients with ALL
Track 6:	Comparison of treatment strategies for young adults with ALL
Track 7:	Evolution of multiagent regimens in pediatric ALL
Track 8:	Asparaginase preparations for ALL
Track 9:	Activity and tolerability of inotuzumab ozogamicin
Track 10:	Recognition and management of immune-related side effects of blinatumomab
Track 11:	Cytokine release syndrome and neurotoxicity with chimeric antigen receptor T-cell (CAR-T) therapy
Track 12:	Anticipated role of CAR-T therapy in clinical practice and potential integration into treatment algorithms for ALL
Track 13:	Limitations of current diagnostic technology for ALL in the community setting
Track 14:	Case: A 35-year-old man presents with fatigue, fever and chills and is diagnosed with FLT3-ITD-negative acute myeloid leukemia (AML)
Track 15:	Mechanism of action and efficacy of midostaurin for patients with FLT3 mutation-positive AML
Track 16:	Investigational FLT3 inhibitors in AML
Track 17:	Liposomal cytarabine/daunorubicin (CPX-351) for secondary AML
Track 18:	IDH1/2 inhibitors for AML
Track 19:	Efficacy of venetoclax alone and in combination with hypomethylating agents for AML
Track 20:	Early data with the use of hedgehog inhibitors for AML
Track 21:	Voluntary market removal of gemtuzumab ozogamicin and the potential for reintroduction
Track 22:	Side effects and toxicities of the antibody-drug conjugate vadastuximab talirine in patients with AML

Interview with Amir T Fathi, MD

Track 1:	Overview of new agents for AML
Track 2:	Cytogenetic evolution between AML diagnosis and relapse and effects on reinduction therapy outcomes
Track 3:	FLT3 inhibitors for relapsed/refractory AML
Track 4:	Hypomethylating agents in older patients with AML
Track 5:	Therapeutic options after treatment with hypomethylating agents for older patients with AML
Track 6:	Specificity and toxicity of various FLT3 inhibitors
Track 7:	Phase III RATIFY study: Midostaurin with daunorubicin/cytarabine induction therapy, with high-dose cytarabine consolidation and as maintenance therapy for newly diagnosed FLT3 mutation-positive AML
Track 8:	Recognition and management of differentiation syndromes in patients with AML treated with IDH or FLT3 inhibitors
Track 9:	Biologic rationale for targeting IDH1/2 mutations
Track 10:	Efficacy and tolerability of the IDH inhibitors enasidenib and ivosidenib in patients with IDH mutations
Track 11:	CPX-351 and venetoclax in AML
Track 12:	Current status of the investigational hedgehog inhibitor glasdegib and the antibody-drug conjugate gemtuzumab ozogamicin
Track 13:	CAR-T therapy and the aurora A kinase inhibitor alisertib for AML
Track 14:	Case: A 50-year-old man with FLT3 wild-type myelodysplastic syndrome experiences disease transformation to FLT3-ITD mutation-positive AML
Track 15:	Case: A 56-year-old man with heavily pretreated AML and a FLT3-ITD mutation receives sorafenib
Track 16:	Conventional treatments and emerging therapies for ALL
Track 17:	Case: A 55-year-old woman with relapsed Philadelphia chromosome-negative B-cell ALL receives blinatumomab
Track 18:	Neurologic toxicities with blinatumomab in the treatment of ALL
Track 19:	Toxicity with different preparations of asparaginase in older patients with ALL
Track 20:	Case: A 45-year-old man with low-risk acute promyelocytic leukemia initially treated with all-trans retinoic acid and arsenic trioxide develops differentiation symptoms

FACULTY

Daniel J DeAngelo, MD, PhD
Director of Clinical and
Translational Research
Adult Leukemia
Institute Physician
Associate Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Amir T Fathi, MD
Assistant Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

EDITOR

Neil Love, MD
Research To Practice
Miami, Florida